Huw Nash is the chief operating officer and chief business officer of Stoke Therapeutics and was previously the founding chief executive officer. An entrepreneur-in-residence at Apple Tree Partners focused on novel therapeutics, Huw has 20 years of experience establishing, funding and growing startup biotechnology companies. Prior to Stoke, Huw was a co-founder and vice president of corporate development for Aileron Therapeutics. He was also a founding scientist of NeoGenesis Pharmaceuticals, where he served as vice president of external collaborations prior to the company’s acquisition by Schering-Plough. Huw received his B.A. in biochemical sciences from Harvard College and earned his Ph.D. in organic chemistry from Harvard University.
Genetic Engineering & Biotechnology News published an article about the history of and recent interest in mRNA-based medications.based in part on an interview with Stoke's Chief Operating and Business Officer, Huw M. Nash, Ph.D.
